How does Zinbryta work?

Zinbryta (daclizumab) is an interleukin-2 receptor blocking antibody for the treatment of adults with relapsing forms of multiple sclerosis (MS). It is thought to work by decreasing T-cells and pro-inflammatory lymphoid tissue inducer cells, and increasing CD56bright natural killer (NK) cells, important cells that help regulate the immune system.

Zinbryta should only be used in patients who have had an inadequate response to two or more multiple sclerosis drugs.

The Zinbryta product label carries a boxed warning advising the serious safety risks, including liver injury and immune disorders.

Zinbryta is available only through a restricted distribution program under a Risk Evaluation and Mitigation Strategy.